A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin ® in healthy Chinese male subjects.

Bibliographic Details
Title:	A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin ^® in healthy Chinese male subjects.
Authors:	Li H; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.; Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China., Zhao X; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.; School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China., Xie J; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China., Zhu X; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.; School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China., Su Y; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.; School of Public Foundation, Bengbu Medical College, Bengbu, Anhui, China., He C; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.; School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China., Ding J; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.; School of Public Foundation, Bengbu Medical College, Bengbu, Anhui, China., Zhu M; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.; School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China., Xu Y; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.; School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China., Wang Y; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.; School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China., Shan R; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.; School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China., Liu B; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China., Ding Y; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China., Liu Y; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China., Zhou H; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China. zhouhuan@bbmc.edu.cn.; School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China. zhouhuan@bbmc.edu.cn.; School of Public Foundation, Bengbu Medical College, Bengbu, Anhui, China. zhouhuan@bbmc.edu.cn., Xie Y; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China. yunqiuxie@bbmc.edu.cn.; Department of Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China. yunqiuxie@bbmc.edu.cn.
Source:	BMC pharmacology & toxicology [BMC Pharmacol Toxicol] 2023 May 27; Vol. 24 (1), pp. 36. Date of Electronic Publication: 2023 May 27.
Publication Type:	Clinical Trial, Phase I; Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: BioMed Central Country of Publication: England NLM ID: 101590449 Publication Model: Electronic Cited Medium: Internet ISSN: 2050-6511 (Electronic) Linking ISSN: 20506511 NLM ISO Abbreviation: BMC Pharmacol Toxicol Subsets: MEDLINE
Database:	MEDLINE Complete
Full text is not displayed to guests.	Login for full access.

Accede al texto completo

Description
ISSN:	2050-6511
DOI:	10.1186/s40360-023-00673-y